6836 BEE CAVE ROAD, AUSTIN, TX
Material Contracts, Other Events
Announces $75M Royalty Funding Agreement To Support The Potential Launch Of MOLBREEVI In Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP), Investor Presentation
Investor Presentation
Shareholder votes
Savara Refused FDA Filing For Molbreevi* BLA in Autoimmune PAP Treatment
Annual Report to Security Holders
Termination of a Material Definitive Agreement
Enters Into Non-Dilutive Debt Financing for Up to $200M with Hercules Capital
Q2
Q1
Amended Annual Report
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence